The FDA approved an expanded label for Iluvien, which is now indicated for the treatment of chronic noninfectious uveitis ...

Feb. 25, 2025 – The FDA has approved a new treatment plan for a long-acting injection, making it easier for people with moderate to severe opioid use disorder (OUD) to start and keep up with ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to ...

Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.

The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain ...

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm tolerability.

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...

Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure.